Botulinum toxin-a treatment reduces human mechanical pain sensitivity and mechanotransduction

Annals of Neurology

Volumn 75, Issue 4, 2014, Pages 591-596

  Paterson, Kathryn ^a   Lolignier, Stéphane ^b   Wood, John N ^b   McMahon, Stephen B ^a   Bennett, David L H ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; HISTAMINE;

ABSENCE OF SIDE EFFECTS; ADULT; ANALGESIC ACTIVITY; ANIMAL CELL; ARTICLE; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPERSENSITIVITY; INNERVATION; MALE; MECHANICAL STIMULATION; MECHANOTRANSDUCTION; MEMBRANE STEADY POTENTIAL; MOUSE; NERVE CELL EXCITABILITY; NERVE FIBER DEGENERATION; NOCICEPTION; NONHUMAN; NORMAL HUMAN; PAIN; PAIN RECEPTOR; PAIN THRESHOLD; PRIORITY JOURNAL; PRURITUS; SENSORY NERVE CELL; SPINAL GANGLION; TEMPORAL SUMMATION;

ADULT; ANIMALS; BOTULINUM TOXINS, TYPE A; CELLS, CULTURED; FEMALE; GANGLIA, SPINAL; HEALTHY VOLUNTEERS; HUMANS; HYPERALGESIA; MALE; MECHANOTRANSDUCTION, CELLULAR; MEMBRANE POTENTIALS; MICE, INBRED C57BL; NEUROMUSCULAR AGENTS; PAIN MEASUREMENT; PAIN THRESHOLD; PATCH-CLAMP TECHNIQUES; PSYCHOPHYSICS; SENSORY RECEPTOR CELLS; YOUNG ADULT;

EID: 84899949570     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24122     Document Type: Article

References (27)

1. Jankovic J, Albanese A, Hallett M,. Unique properties of botulinum toxins. Toxicon 2009; 54: 675.
2. Cui M, Khanijou S, Rubino J, Aoki KR,. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004; 107: 125-133.
3. Luvisetto S, Marinelli S, Cobianchi S, Pavone F,. Anti-allodynic efficacy of botulinum neurotoxin A in a model of neuropathic pain. Neuroscience 2007; 145: 1-4.
4. Frampton JE,. OnabotulinumtoxinA (BOTOX®): a review of its use in the prophylaxis of headaches in adults with chronic migraine. Drugs 2012; 72: 825-845.
5. Ranoux D, Attal N, Morain F, Bouhassira D,. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol 2008; 64: 274-283.
6. Dolly JO, O'Connell MA,. Neurotherapeutics to inhibit exocytosis from sensory neurons for the control of chronic pain. Curr Opin Pharmacol 2012; 12: 100-108.
7. Meng J, Wang J, Lawrence G, Dolly JO,. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J Cell Sci 2007; 120 (pt 16): 2864-2874.
8. Gazerani P, Staahl C, Drewes AM, Arendt-Nielsen L,. The effects of botulinum toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain 2006; 122: 315-325.
9. Matak I, Bach-Rojecky L, Filipovic B, Lackovic Z,. Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A. Neuroscience 2011; 186: 201-207.
10. Dubin AE, Patapoutian A,. Nociceptors: the sensors of the pain pathway. J Clin Invest 2010; 120: 3760-3772.
11. von Hehn CA, Baron R, Woolf CJ,. Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. Neuron 2012; 73: 638-652.
12. Drew LJ, Rugiero F, Cesare P, et al. High-threshold mechanosensitive ion channels blocked by a novel conopeptide mediate pressure-evoked pain. PloS One 2007; 2: e515.
13. Rolke R, Baron R, Maier C, et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values. Pain 2006; 123: 231-243.
14. Kremeyer B, Lopera F, Cox JJ, et al. A gain-of-function mutation in TRPA1 causes familial episodic pain syndrome. Neuron 2010; 66: 671-680.
15. Minor V,. Ein neues verfahren zu der klinischen untersuchung der schweissabsonderung. Dtsch Z Nervenheilkd 1928: 101302-101307.
16. Ramirez JD, Barnes PR, Mills KR, Bennett DL,. Intermediate Charcot-Marie-Tooth disease due to a novel Trp101Stop myelin protein zero mutation associated with debilitating neuropathic pain. Pain 2012; 153: 1763-1768.
17. Simone DA, Nolano M, Johnson T, et al. Intradermal injection of capsaicin in humans produces degeneration and subsequent reinnervation of epidermal nerve fibers: correlation with sensory function. J Neurosci 1998; 18: 8947-8959.
18. Blersch W, Schulte-Mattler WJ, Przywara S, et al. Botulinum toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebo-controlled, randomized study. J Neurol Sci 2002; 205: 59-63.
19. Sycha T, Samal D, Chizh B, et al. A lack of antinociceptive or antiinflammatory effect of botulinum toxin A in an inflammatory human pain model. Anesth Analg 2006; 102: 509-516.
20. Ziegler EA, Magerl W, Meyer RA, Treede RD,. Secondary hyperalgesia to punctate mechanical stimuli. Central sensitization to A-fibre nociceptor input. Brain 1999; 122 (pt 12): 2245-2257.
21. Yiangou Y, Anand U, Otto WR, et al. Increased levels of SV2A botulinum neurotoxin receptor in clinical sensory disorders and functional effects of botulinum toxins A and E in cultured human sensory neurons. J Pain Res 2011; 4: 347-355.
22. Vilceanu D, Stucky CL,. TRPA1 mediates mechanical currents in the plasma membrane of mouse sensory neurons. PloS One 2010; 5: e12177.
23. Kerstein PC, del Camino D, Moran MM, Stucky CL,. Pharmacological blockade of TRPA1 inhibits mechanical firing in nociceptors. Mol Pain 2009; 5: 19.
24. Rugiero F, Wood JN,. The mechanosensitive cell line ND-C does not express functional thermoTRP channels. Neuropharmacology 2009; 56: 1138-1146.
25. Di Castro A, Drew LJ, Wood JN, Cesare P,. Modulation of sensory neuron mechanotransduction by PKC- and nerve growth factor-dependent pathways. Proc Natl Acad Sci U S A 2006; 103: 4699-4704.
26. Meng J, Ovsepian SV, Wang J, et al. Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential. J Neurosci 2009; 29: 4981-4992.
27. Carmichael NM, Dostrovsky JO, Charlton MP,. Peptide-mediated transdermal delivery of botulinum neurotoxin type A reduces neurogenic inflammation in the skin. Pain 2010; 149: 316-324.